ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 301c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($3.10), $3.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.64 million versus the consensus estimate of $37.09 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Winnebago Industries (WGO) Misses Q3 EPS by 11c ; Offers Guidance
• SanDisk stock target lifted by Citi on continued demand strength
• Berenberg Downgrades Berkeley Group Holdings Plc. (BKG:LN) (BKGFF) to Hold